News

July 15, 2020

Arkuda Therapeutics Appoints Pascale Witz to Board of Directors

Watertown, MA – July 15, 2020 – Arkuda Therapeutics, a company leveraging new insights into progranulin (PGRN) and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease, today announced the appointment of Pascale Witz, MBA, MSc, to its Board of Directors.

“Pascale is an accomplished business leader and biotech industry advisor with a proven track record of developing programs from research to commercialization,” said Gerhard Koenig, PhD, President and CEO of Arkuda Therapeutics. “Her wealth of experience and counsel will be extremely valuable as we advance our therapeutic pipeline to treat progranulin-related frontotemporal dementia (FTD-GRN) and other neurodegenerative diseases.”

Ms. Witz brings nearly three decades of global pharmaceutical and healthcare management experience to Arkuda’s Board. She currently provides strategic consulting services to investors and life science companies through PWH Advisors, a New York-based consulting firm she founded. Previously Ms. Witz served as Executive Vice President of Global Diabetes and Cardiovascular of Sanofi S.A., where she launched multiple medicines and strengthened the company pipeline through licensing and partnerships, as well as on Sanofi’s executive committee. Prior to Sanofi, she held positions of increasing responsibility over a 17-year career at GE Healthcare, most recently serving as President and CEO of its $2 billion pharmaceutical diagnostics business.

Ms. Witz received a Master of Business Administration in Economics and Marketing from INSEAD, Fontainebleau, France, and a Master of Science in Biochemistry from INSA Lyon, France. She currently serves on the Board of Directors for Horizon Therapeutics Plc, PerkinElmer, Inc., Regulus Therapeutics, Inc. and Fresenius Medical Care AG & Co. KGaA. In addition, she is a board member for the Global Alzheimer’s Platform Foundation, a non-profit organization dedicated to accelerating the delivery of innovative therapies to those affected by Alzheimer’s disease.

 

# # #

 

About Arkuda Therapeutics
Arkuda Therapeutics is a biotechnology company harnessing new and evolving insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead program aims to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene. Beyond FTD-GRN, Arkuda is exploring the therapeutic potential of progranulin and additional lysosomal biology in other neurodegenerative diseases. launched in November 2019 with $44 million from leading life science investors including Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, and Mission BioCapital. To learn more visit www.arkudatx.com.

 

Media Contact:
Lissette Steele
Verge Scientific Communications
202.930.4762
lsteele@vergescientific.com

MEDIA CONTACT

Lissette Steele
Verge Scientific Communications
lsteele@vergescientific.com
202.930.4762